Navigation Links
Ranbaxy Commends New IMS Study Which Credits Generic Prescription Drugs With $1 Trillion Savings In U.S. Health Care Costs Over Past 10 Years
Date:8/2/2012

PRINCETON, N.J., Aug. 2, 2012 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI) today acknowledged an important, new study released by the Generic Pharmaceutical Association (GPhA) which further demonstrates the vital role played by the generic pharmaceutical industry in lowering prescription costs for consumers and the U.S. health care system.

The fourth annual Generic Drug Savings study reveals remarkable reductions in healthcare costs over the past 10 years (from 2002 to 2011). The research—conducted by the IMS Institute for Healthcare Informatics, the leading provider of market intelligence to the pharmaceutical and health care industries for over 55 years—reveals a $1 trillion savings to consumers, patients and the U.S. health care system due to the use of generic prescription drugs. The study found that in 2011 alone, the use of generic drugs in place of their branded counterparts generated nearly $193 billion in savings, an average of $1 billion every other day.

"We are proud of Ranbaxy's contribution to such a considerable record of savings for consumers and reduction in U.S. health care costs," said Venkat Krishnan, Senior Vice President and Regional Director – Americas.  "Through the diligent work of employees in every division of our company, Ranbaxy is committed to providing patients across the country with affordable and accessible, safe and effective generic prescription drugs that enhance their health and well-being."

He added, "Today, thousands of generic drugs are available in the U.S., and all are manufactured and inspected under the same strict guidelines as brand name drugs.  With every prescription filled (some 80 percent of all prescriptions written in 2011), patients taking generics receive the same medicine, with the same quality and result, but at a much lower cost. We are happy to be a part of the solution to the problem of escalating costs facing the U.S. health care system."

According to the GPhA study, the proven track record of savings for consumers using traditional generic drugs can be duplicated in the biopharmaceutical market. The approval of biosimilars will inject the competition needed in the biologic market to lower costs and provide significant savings for patients in need of these life saving treatments.

"We view biologics as the next generation of generic innovation, and Ranbaxy has been hard at work positioning itself as a player in this space. It is important that the FDA maintains its commitment to biosimilars and that it ensures a workable pathway for such life saving treatments in the U.S. market," Krishnan concluded.

Since the implementation of the Hatch-Waxman Act in 1984, which opened the door to the generic pharmaceutical industry, consumers and patients have had a steady stream of lower cost, safe and effective generic treatments.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company.  RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. health care system.


'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA
2. ACEP Commends Congress For Passing Legislation That Addresses Drug Shortages As Well As "Bath Salts"
3. Boston Scientific Commends Congress on Passage of Bill Reauthorizing Medical Device User Fees
4. Pew Commends U.S. Congress for Passing FDA User Fee Legislation
5. AdvaMed Commends House Progress on Repealing Medical Device Tax
6. In Pilot Study, a Peptide Controls Blood Sugar in People with Congenital Hyperinsulinism
7. Concordia Study Indicates Obesity is Becoming the Nations Top Health Issue
8. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
9. French Government Agrees to Fund Study of the PneumRx RePneu Lung Volume Reduction Coil
10. Gentris Corporation Announces Collaboration to Study Blood Stability
11. New Study Reveals Wide Variation in Blood Transfusion Practices During Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
Breaking Medicine News(10 mins):